ReviewScientific reports2024
Nanoparticles as a novel key driver for the isolation and detection of circulating tumour cells.
Review in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Theranostic Smart Bionanosensors for Solid Tumors: Advances, Challenges, and Future Directions.Applied biochemistry and biotechnology · 2026Review
- Circulating Tumour Cells as Potential Biomarkers for Oral Squamous Cell Carcinoma.Molecules (Basel, Switzerland) · 2026Review
- Isolation and typing techniques for circulating tumor cells.Biomarker research · 2026Review
- Epi-liquidomics: redefining cancer diagnostics through epigenetic profiling.Frontiers in epigenetics and epigenomics · 2026Review
- Nanotechnology-Enabled Diagnosis and Treatment of Hepatocellular Carcinoma: Theranostics, Combination Regimens, and Translation.International journal of nanomedicine · 2026Review
- Cellulose-Encapsulated Magnetite Nanoparticles for Spiking of Tumor Cells Positive for the Membrane-Bound Hsp70.International journal of molecular sciences · 2025Article
- Enhancing detection and monitoring of circulating tumor cells: Integrative approaches in liquid biopsy advances.The journal of liquid biopsy · 2025Review
- A Concise Review of the Control and Assessment of Magnetic Affinity Particle Assembly for Live Cell Analyses: State of the Art and Challenges.Materials (Basel, Switzerland) · 2025Review
- Minimal Residual Disease in Metastatic Soft Tissue Sarcoma.Current treatment options in oncology · 2025Review
- Utilizing Nanomaterials in Microfluidic Devices for Disease Detection and Treatment.Nanomaterials (Basel, Switzerland) · 2025Review
- Advances and future directions of aptamer-functionalized nanoparticles for point-of-care diseases diagnosis.Biology methods & protocols · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating tumour cells (CTCs), derived from primary tumours, play a pivotal role in cancer metastasis by migrating into the peripheral bloodstream. These cells are paramount in clinical research, serving as early diagnostic markers for metastatic cancer. Analysing CTC counts and their biomarker characteristics can provide invaluable insights into tumour identification, profiling, and metastatic capabilities. However, the rarity and diverse nature of CTCs in the bloodstream present significant challenges to their isolation and detection, especially in the initial stages of metastasis. Recent advancements in nanotechnology have led to the development of innovative CTC separation and detection methods. This review focuses on applying nanoparticles, nanomaterials, and microfluidic platforms to simplify the isolation and detection of CTCs. The infusion of nanotechnology in this field marks a crucial turning point, enabling the necessary progress to advance CTC research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.